Effects on Melanoma Cell Lines Suggest No Significant Risk of Melanoma Under Cladribine Treatment
| Autor: | Sophie Tartare-Deckert, Mikael Cohen, Berestjuk I, Christine Lebrun-Frenay |
|---|---|
| Přispěvatelé: | Centre méditerranéen de médecine moléculaire (C3M), Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Université Côte d'Azur (UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Unité de Recherche Clinique de la Côte d’Azur [Nice] (URRIS UR2CA), Université Côte d'Azur (UCA), TARTARE-DECKERT, Sophie, Université Nice Sophia Antipolis (1965 - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Côte d'Azur (UCA) |
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
[SDV]Life Sciences [q-bio]
Purine analogue [SDV.CAN]Life Sciences [q-bio]/Cancer [SDV.BC]Life Sciences [q-bio]/Cellular Biology Multiple sclerosis 03 medical and health sciences 0302 clinical medicine [SDV.CAN] Life Sciences [q-bio]/Cancer medicine 030212 general & internal medicine Significant risk RC346-429 Cladribine [SDV.BC] Life Sciences [q-bio]/Cellular Biology Melanoma business.industry Cell growth Brief Report [SCCO.NEUR]Cognitive science/Neuroscience [SCCO.NEUR] Cognitive science/Neuroscience Immunosuppressors medicine.disease 3. Good health [SDV] Life Sciences [q-bio] Neurology Mechanism of action Melanoma cell line Cancer research Neurology. Diseases of the nervous system Neurology (clinical) medicine.symptom business 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Neurology and Therapy Neurology and Therapy, 2020, Online ahead of print. ⟨10.1007/s40120-020-00204-5⟩ Neurology and Therapy, Springer Healthcare, 2020, Online ahead of print. ⟨10.1007/s40120-020-00204-5⟩ Neurology and Therapy, Vol 9, Iss 2, Pp 599-604 (2020) |
| ISSN: | 2193-8253 2193-6536 |
| Popis: | International audience; Cladribine is an oral synthetic purine analog that depletes lymphocytes and induces a dose-dependent reduction of T and B cells. It was approved for the therapy of highly active relapsing-remitting multiple sclerosis. Given cladribine's mechanism of action, an increased risk of malignancies was suspected from the number of cancers that occurred in the 3.5 mg/kg-treated arm (CLARITY study). We showed that cladribine inhibits cell proliferation on three melanoma cell lines tested, irrespectively of their mutational oncogenic status and invasive/metastatic potential. Aggregated safety data demonstrated that the risk of melanoma is not confirmed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink